Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19901886 | 0.81 | GPR55 (0.39) | GPR55SMYD3CHRNB2CHRNA4 | |
| SCHEMBL798986 | 0.80 | GPR55 (0.38) | GPR55SMYD3CHRNB2CHRNA4 | |
| SCHEMBL20885282 | 0.77 | GPR55 (0.36) | GPR55SMYD3CHRNB2CHRNA4 | |
| SCHEMBL22788203 | 0.75 | GPR55 (0.37) | GPR55SMYD3CHRNB2CHRNA4 | |
| SCHEMBL240843 | 0.72 | SMYD3 (0.39) | SMYD3CHRNB2CHRNA4 | |
| SCHEMBL20445161 | 0.69 | ALDH1A1 (0.33) | GPR55 | |
| SCHEMBL13534147 | 0.68 | GPR55 (0.35) | GPR55SMYD3CHRNB2CHRNA4 | |
| SCHEMBL26169682 | 0.68 | CYP2A6 (0.36) | — | |
| SCHEMBL21895812 | 0.67 | — | — | |
| SCHEMBL18964946 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647724-B2 | Selective estrogen receptor degraders and uses thereof | INVENTISBIO INC. (KY) | 2020-05-12 | — | — | US | disclosed |
| US-20200040001-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF | INVENTISBIO LLC | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647724-B2 | Selective estrogen receptor degraders and uses thereof | ESR1, ESRRA, ESR2 | GPR55 213/4885SMYD3 4527/4885CHRNB2 2726/4885 |
| US-20200040001-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF | ESR1, ESRRA, ESR2 | GPR55 213/4885SMYD3 4527/4885CHRNB2 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.